1. Michel de Lorgeril et al. “Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications after Myocardial Infarction: Final Report of the Lyon Diet Heart Study,” Circulation 99, no. 6 (1999): 779–85.
2. Channing Laboratory, “History,” The Nurses’ Health Study, www.channing.harvard.edu/nhs/?page_id=70.
3. Ibid.
4. Michel de Lorgeril et al., “Mediterranean Alpha-Linolenic Acid-Rich Diet in Secondary Prevention of Coronary Heart Disease.” The Lancet, no. 143 (1994): 1454 –59.
5. John Kastelein et al., “Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia,” New England Journal of Medicine 358, no. 14 (2008): 1431–43.
6. F.B. Hu et al., “Primary Prevention of Coronary Heart Disease in Women Through Diet and Lifestyle,” New England Journal of Medicine 343, no. 1 (2000): 16–12.
7. Ibid.
1. Matthew Herper, “America’s Most Popular Drugs,” Forbes, April 19, 2011, www.forbes.com/sites/matthewherper/2011/04/19/americas-most-popular-drugs.
2. Daniel J. DeNoon, “The 10 Most Prescribed Drugs,” WebMD Health News, April 20, 2011, www.webmd.com/news/20110420/the-10-most-prescribed-drugs.
3. University of Minnesota, School of Public Health, Health Revolutionary: The Life and Work of Ancel Keys, PDF transcript of a video documentary, 2002, www.asph.org/movies/keys.pdf.
4. Ancel Keys, ed., Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease (Cambridge, MA: Harvard University Press, 1980); Ancel Keys, “Coronary Heart Disease in Seven Countries,” Circulation 41, no. 1 (1970): 1–211.
5. Malcolm Kendrick, About Cavemen’s Diet, online discussion board comments posted to the website of the International Network of Cholesterol Skeptics, February 12, 2002, www.thincs.org/discuss.cavemen.htm.
6. Malcolm Kendrick, The Great Cholesterol Con (London: John Blake, 2007), 53.
7. Uffe Ravnskov, Ignore the Awkward (Seattle: CreateSpace, 2010).
8. I.H. Page et al., “Dietary Fat and Its Relation to Heart Attacks and Strokes,” Circulation 23 (1961): 133–36.
9. Gary Taubes, “The Soft Science of Dietary Fat,” Science 291, no. 5513 (2001): 2536–45.
10. Ibid.
11. University of Maryland, “Trans Fats 101,” University of Maryland Medical Center, last modified November 3, 2010, www.umm.edu/features/transfats.htm.
12. Multiple Risk Factor Intervention Trial Research Group, “Multiple Risk Factor Intervention Trial,” Journal of the American Medical Association 248, no. 12 (1982): 1465–77.
13. Ibid.
14. Mohammad Madjid et al., “Thermal Detection of Vulnerable Plaque,” American Journal of Cardiology 90, no. 10 (2002): L36–L39.
15. W. Castelli, “Concerning the Possibility of a Nut . . . ” Archives of Internal Medicine 152, no. 7 (1992): 1371–72.
16. “The Lipid Research Clinics Coronary Primary Prevention Trial Results,” Journal of the American Medical Association 251, no. 3 (1984): 351–74.
17. G.V. Mann, “Coronary Heart Disease—‘Doing the Wrong Things,’” Nutrition Today 20, no. 4 (1985): 12–14.
18. Ibid.
19. Michael F. Oliver, “Consensus or Nonsensus Conferences on Coronary Heart Disease,” The Lancet 325, no. 8437 (1985): 1087–89.
20. National Institutes of Health Consensus Development Conference Statement, December 10–12, 1984.
21. National Institutes of Health, “News from the Women’s Health Initiative: Reducing Total Fat Intake May Have Small Effect on Risk of Breast Cancer, No Effect on Risk of Colorectal Cancer, Heart Disease, or Stroke,” NIH News, last modified February 7, 2006, www.nih.gov/news/pr/feb2006/nhlbi-07.htm.
22. Alice Ottoboni and Fred Ottoboni, “Low-Fat Diet and Chronic Disease Prevention: The Women’s Health Initiative and Its Reception,” Journal of American Physicians and Surgeons 12, no. 1 (2007): 10–13.
23. Gina Kolata, “Low-Fat Diet Does Not Cut Health Risks, Study Finds,” New York Times, February 8, 2006.
24. Dwight Lundell, The Cure for Heart Disease (Scottsdale: Publishing Intellect, 2012).
25. Michel de Lorgeril, A Near-Perfect Sexual Crime: Statins Against Cholesterol (France: A4Set, 2011).
1. J.M. Gaziano et al., “Fasting Triglycerides, High-Density Lipoprotein, and Risk of Myocardial Infarction,” Circulation 96, no. 8 (1997): 2520–25. http://www.ncbi.nlm.nih.gov/pubmed/9355888.
2. Denham Harman, “Aging: A Theory Based on Free Radical and Radiation Chemistry,” Journal of Gerontology 11, no. 3 (1956): 298–300; Denham Harman, “Free Radical Theory of Aging,” in Free Radicals and Aging, eds. I. Emerit and B. Chance (Basel, Switzerland: Birkhäuser, 1992).
3. Science Daily, “Some Good Cholesterol Is Actually Bad, Study Shows,” Science Daily, accessed September 12, 2011, www.sciencedaily.com/releases/2008/12/081201081713.htm.
4. Ibid.
5. Dwight Lundell, The Cure for Heart Disease (Scottsdale: Publishing Intellect, 2012).
1. Mark Houston, M.D., M.S., director of the Hypertension Institute in Tennessee, May 2, 2012, telephone communication.
2. David C. Goff et al., “Insulin Sensitivity and the Rise of Incident Hypertension,” Diabetes Care 26, no. 3 (2003): 805–9, doi.
3. Science Daily, “Too Much Insulin a Bad Thing for the Heart?” Science Daily, last modified April 19, 2010, www.sciencedaily.com/releases/2010/04/100419233109.htm.
4. V. Marigliano et al., “Normal Values in Extreme Old Age,” Annals of the New York Academy of Sciences 673 (1992): 23–28.
5. Jeff O’Connell, Sugar Nation: The Hidden Truth Behind America’s Deadliest Habit and the Simple Way to Beat It (New York: Hyperion Books, 2011), 78.
6. Ibid.
7. Gary Taubes, “Is Sugar Toxic?” New York Times Magazine, April 13, 2011.
8. American Association of Clinical Endocrinologists, “Findings and Recommendations on the Insulin Resistance Syndrome,” American Association of Clinical Endocrinologists, Washington, D.C., August 25–26, 2002.
9. Ibid.
10. Michael Miller, “What Is the Association Between the Triglyceride to High-density Lipoprotein Cholesterol Ratio and Insulin Resistance?” Medscape Education, www.medscape.org/viewarticle/588474; T. McLaughlin et al., “Use of Metabolic Markers to Identify Overweight Individuals Who Are Insulin Resistant,” Annals of Internal Medicine 138, no. 10 (2003): 802–9.
11. Johns Hopkins Medicine, “The New Blood Lipid Tests—Sizing Up LDL Cholesterol,” Johns Hopkins Health Alerts, last modified on June 13, 2008, www.johnshopkinshealthalerts.com/reports/heart_health/1886-1.html.
12. Taubes, “Is Sugar Toxic?”
13. George V. Mann, Coronary Heart Disease: The Dietary Sense and Nonsense (London: Janus, 1993).
14. George V. Mann et al., “Atherosclerosis in the Masai,” American Journal of Epidemiology 95, no. 1 (1972): 26–37.
15. John Yudkin, Sweet and Dangerous (New York: Wyden, 1972).
16. Ancel Keys, “Letter: Normal Plasma Cholesterol in a Man Who Eats 25 Eggs a Day,” New England Journal of Medicine 325, no. 8 (1991): 584.
17. National Institutes of Health. “National Cholesterol Education Program,” National Heart, Lung, and Blood Institute, last modified in October 2011, www.nhlbi.nih.gov/about/ncep.
18. www.who.int/dietphysicalactivity/publications
19. Juliet Eilperin, “U.S. Sugar Industry Targets New Study,” Washington Post, April 23, 2003, www.washingtonpost.com/ac2/wp-dyn/A17583-2003Apr22?language=printer.
20. John Casey, “The Hidden Ingredient That Can Sabotage Your Diet,” MedicineNet, last modified January 3, 2005, www.medicinenet.com/script/main/art.asp?articlekey=56589.
21. Taubes, “Is Sugar Toxic?”
22. Luc Tappy et al., “Metabolic Effects of Fructose and the Worldwide Increase in Obesity,” Physiological Reviews 90, no. 1 (2010): 23–46; Mirjam Dirlewanger et al., “Effects of Fructose on Hepatic Glucose Metabolism in Humans,” American Journal of Physiology, Endocrinology, and Metabolism 279, no. 4 (2000): E907–11.
23. Sharon S. Elliott et al., “Fructose, Weight Gain, and the Insulin Resistance Syndrome,” American Journal of Clinical Nutrition 76, no. 5 (2002): 911–22; K.A. Lê and L. Tappy, “Metabolic Effects of Fructose,” Current Opinion in Clinical Nutrition and Metabolic Care 9, no. 4 (2006): 469–75; Y. Rayssiguier et al., “High Fructose Consumption Combined with Low Dietary Magnesium Intake May Increase the Incidence of the Metabolic Syndrome by Inducing Inflammation,” Magnesium Research Journal 19, no. 4 (2006): 237–43.
24. K. Adeli and A.C. Rutledge, “Fructose and the Metabolic Syndrome: Pathophysiology and Molecular Mechanisms,” Nutrition Reviews 65, no. 6 (2007): S13–S23; K.A. Lê and L. Tappy, “Metabolic Effects of Fructose.”
25. Science Daily. “Fructose Metabolism by the Brain Increases Food Intake and Obesity, Study Suggests,” Science Daily, www.sciencedaily.com/releases/2009/03/090325091811.htm.
1. Frank B. Hu et al., “Meta-analysis of Prospective Cohort Studies Evaluating the Association of Saturated Fat with Cardiovascular Disease,” American Journal of Clinical Nutrition 91, no. 3 (2010): 502–9.
2. R.S. Kuipers et al., “Saturated Fat, Carbohydrates, and Cardiovascular Disease,” Netherlands Journal of Medicine 69, no. 9 (2011): 372–78.
3. F. de Meester and A.P. Simopoulos, eds., “A Balanced Omega-6/Omega-3 Fatty Acid Ratio, Cholesterol and Coronary Heart Disease,” World Review of Nutrition and Dietetics 100 (2009): 1–21; T. Hamazaki, Y. Kirihara, and Y. Ogushi, “Blood Cholesterol as a Good Marker of Health in Japan,” World Review of Nutrition and Dietetics 100 (2009): 63–70.
4. Japan Atherosclerosis Society, “Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases,” Journal of Atherosclerosis and Thrombosis 14, no. 2 (2007): 5–57; de Meester and Simopoulos, “A Balanced Omega-6/Omega-3 Fatty Acid Ratio, Cholesterol and Coronary Heart Disease.”
5. T. Hamazaki, et al., “Blood Cholesterol as a Good Marker of Health in Japan,” World Review of Nutrition and Dietetics 100 (2009): 63–70; de Meester and Simopoulos, “A Balanced Omega-6/Omega-3 Fatty Acid Ratio.”
6. D.M. Dreon et al., “Change in Dietary Saturated Fat Intake Is Correlated with Change in Mass of Large Low-density Lipoprotein Particles in Men,” American Journal of Clinical Nutrition 67, no. 5 (1998): 828–36.
7. David M. Herrington, et al., “Dietary Fats, Carbohydrate, and Progression of Coronary Atherosclerosis in Postmenopausal Women,” American Journal of Clinical Nutrition 80, no. 5 (2004): 1175–84.
8. Ibid.
9. Robert H. Knopp and Barbara M. Retzlaff, “Saturated Fat Prevents Coronary Artery Disease? An American Paradox,” American Journal of Clinical Nutrition 80, no. 5 (2004): 1102–3.
10. M.B. Katan et al., “Dietary Oils, Serum Lipoproteins, and Coronary Heart Disease,” American Journal of Clinical Nutrition 61, no. 6 (1995): 1368S–73S.
11. S. Liu et al., “A Prospective Study of Dietary Glycemic Load, Carbohydrate Intake, and Risk of Coronary Heart Disease in U.S. Women,” American Journal of Clinical Nutrition 71, no. 6 (2000): 1455–61.
12. M.U. Jakobsen et al., “Intake of Carbohydrates Compared with Intake of Saturated Fatty Acids and Risk of Myocardial Infarction: Importance of the Glycemic Index,” American Journal of Clinical Nutrition 91, no. 6 (2010): 1764–68.
13. Ibid.
14. Ibid.
15. www.ncbi.nlm.nih.gov/pubmed/16904539.
16. R.S. Kuipers et al., “Saturated Fat, Carbohydrates, and Cardiovascular Disease,” Netherlands Journal of Medicine 69, no. 9 (2011): 372–78.
17. A.P. Simopoulos, “Evolutionary Aspects of the Dietary Omega-6:Omega-3 Fatty Acid Ratio: Medical Implications,” World Review of Nutrition and Dietetics 100 (2009): 1–21.
18. Ibid; A.P. Simopoulos, “Overview of Evolutionary Aspects of w3 Fatty Acids in the Diet,” World Review of Nutrition and Dietetics 83 (1998): 1–11.
19. R.O. Adolf et al., “Dietary Linoleic Acid Influences Desaturation and Acylation of Deuterium-labeled Linoleic and Linolenic Acids in Young Adult Males,” Biochimica et Biophysica Acta 1213, no. 3 (1994): 277–88; Ghafoorunissa and M. Indu, “N-3 Fatty Acids in Indian Diets—Comparison of the Effects of Precursor (Alpha-linolenic Acid) vs. Product (Long Chain N-3 Polyunsaturated Fatty Acids),” Nutrition Research 12, nos. 4–5 (1992): 569–82.
20. A.P. Simopoulos,“Evolutionary Aspects of the Dietary Omega-6:Omega-3 Fatty Acid Ratio: Medical Implications,” World Review of Nutrition and Dietetics 100 (2009): 1–21.
21. A.P. Simopoulos, “Overview of Evolutionary Aspects of w3 Fatty Acids in the Diet.”
22. P. Reaven et al., “Effects of Oleate-rich and Linoleate-rich Diets on the Susceptibility of Low-density Lipoprotein to Oxidative Modification in Mildly Hypercholesterolemic Subjects,” Journal of Clinical Investigation 91, no. 2 (1993): 668–76.
23. L.G. Cleland, “Linoleate Inhibits EPA Incorporation from Dietary Fish Oil Supplements in Human Subjects,” American Journal of Clinical Nutrition 55, no. 2 (1992): 395–99.
24. William E.M. Lands, “Diets Could Prevent Many Diseases,” Lipids 38. no. 4 (2003): 317–21.
25. Ibid.
26. William E.M. Lands, “A Critique of Paradoxes in Current Advice on Dietary Lipids,” Progress in Lipid Research 47, no. 2 (2008): 77–106.
1. A.E. Dorr et al., “Colestipol Hydrochloride in Hypercholesterolemic Patients—Effect on Serum Cholesterol and Mortality,” Journal of Chronic Diseases 31, no. 1 (1978): 5.
2. Jeremiah Stamler et al., “Effectiveness of Estrogens for the Long-Term Therapy of Middle-Aged Men with a History of Myocardial Infarction,” in Coronary Heart Disease: Seventh Hahnemann Symposium, eds. William Likoff and John Henry Moyer (New York: Grune & Stratton, 1963), 416.
3. Duane Graveline, Lipitor: Thief of Memory (Duane Graveline, 2006), www.spacedoc.com/lipitor_thief_of_memory.html.
4. Dan Kuester, “Cholesterol-Reducing Drugs May Lessen Brain Function, Says ISU Researcher,” Iowa State University, last modified February 23, 2009, www2.iastate.edu/~nscentral/news/2009/feb/shin.shtml.
5. Ibid.
6. Melinda Beck, “Can a Drug That Helps Hearts Be Harmful to the Brain?” Wall Street Journal, February 12, 2008.
7. C. Iribarren et al., “Serum Total Cholesterol and Risk of Hospitalization and Death from Respiratory Disease,” International Journal of Epidemiology 26, no. 6 (1997): 1191–1202; C. Iribarren et al., “Cohort Study of Serum Total Cholesterol and In-Hospital Incidence of Infectious Diseases,” Epidemiology and Infection 121, no. 2 (1998): 335–47; J.D. Neaton and D.N. Wentworth, “Low Serum Cholesterol and Risk of Death from AIDS,” AIDS 11, no. 7 (1997): 929–30.
8. D. Jacobs et al., “Report of the Conference on Low Blood Cholesterol: Mortality Associations,” Circulation 86, no. 3 (1992): 1046–60.
9. Iribarren et al., “Serum Total Cholesterol”; C. Iribarren et al., “Cohort Study of Serum Total Cholesterol.”
10. J.D. Neaton and D.N. Wentworth, “Low Serum Cholesterol and Risk of Death from AIDS.”
11. Jonathan Kantor, “Prevalence of Erectile Dysfunction and Active Depression: An Analytic Cross-Sectional Study of General Medical Patients,” American Journal of Epidemiology 156, no. 11 (2002): 1035–42.
12. M. Kanat et al., “A Multi-Center, Open Label, Crossover Designed Prospective Study Evaluatiing the Effects of Lipid-lowering Treatment on Steroid Synthesis in Patients with Type 2 Diabetes (MODEST Study),” Journal of Endocrinology Investigation 32, no. 10 (2009): 852–56; R.D. Stanworth et al., “Statin Therapy is Associated with Lower Total but not Bioavailable or Free Testosterone in Men with Type 2 Diabetes,” Diabetes Care 32, no. 4 (2009): 541–46; A.S. Dobbs et al., “Effects of High-Dose Simvastatin on Adrenal and Gonadal Steroidogenesis in Men with Hypercholesterolemia,” Metabolism 49, no. 9 (2000): 1234–38; A.S. Dobs et al., “Effects of Simvastatin and Pravastatin on Gonadal Function in Male Hypercholesterolemic Patients,” Metabolism 49, no. 1 (2000): 115–21; M.T. Hyyppä et al., “Does Simvastatin Affect Mood and Steroid Hormone Levels in Hypercholesterolemic Men? A Randomized Double-Blind Trial,” Psychoneuroendocrinology 28, no. 2 (2003): 181–94.
13. B. Banaszewska et al., “Effects of Simvastatin and Oral Contraceptive Agent on Polycystic Ovary Syndrome: Prospective, Randomized, Crossover Trial,” Journal of Clinical Endocrinology & Metabolism 92, no. 2 (2007): 456–61; T. Sathyapalan et al., “The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study,” Journal of Clinical Endocrinology & Metabolism 94, no. 1 (2009): 103–108.
14. C. Do et al., “Statins and Erectile Dysfunction: Results of a Case/Non-Case Study using the French Pharmacovigilance System Database,” Drug Safety 32, no. 7 (2009): 591–97.
15. C.J. Malkin et al., “Low Serum Testosterone and Increased Mortality in Men with Coronary Heart Disease,” Heart 96, no. 22 (2010): 1821–25.
16. S. Shrivastava et al., “A. Chronic Cholesterol Depletion Using Statin Impairs the Function and Dynamics of Human Serotonin (1A) Receptors,” Biochemistry 49, no. 26 (2010): 5426–35; L.N. Johnson-Anuna et al., “Chronic Administration of Statins Alters Multiple Gene Expression Patterns in Mouse Cerebral Cortex,” Journal of Pharmacology and Experimental Therapeutics 312, no. 2 (2005): 786–93. A. Linetti et al., “Cholesterol Reduction Impairs Exocytosis of Synaptic Vesicles,” Journal of Cell Science 123, no. 4 (2010): 595–605.
17. T.B. Horwich et al., “Low Serum Total Cholesterol Is Associated with Marked Increase in Mortality in Advanced Heart Failure,” Journal of Cardiac Failure 8, no. 4 (2002): 216–24.
18. Sonia Brescianini et al., “Low Total Cholesterol and Increased Risk of Dying: Are Low Levels Clinical Warning Signs in the Elderly? Results from the Italian Longitudinal Study on Aging,” Journal of the American Geriatrics Society 51, no. 7 (2003): 991–96.
19. A. Alawi et al., “Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer,” Journal of the American College of Cardiology 50, no. 5 (2007): 409–18.
20. David Preiss et al., “Risk of Incident Diabetes with Intensive-Dose Compared with Moderate-Dose Statin Therapy,” Journal of the American Medical Association 305, no. 24 (2011): 2556–64.
21. www.spacedoc.com, Statin Drugs, accessed May 2, 2012
22. Joe Graedon and Terry Graedon, “Patients Find Statins Can Have Side Effects,” The People’s Pharmacy, April 18, 2005, accessed January 4, 2012, www.peoplespharmacy.com/2005/04/18/patients-find-s.
23. Joe Graedon and Terry Graedon, “Can Statins Cause Debilitating Muscle Pain,” The People’s Pharmacy, April 18, 2005, accessed January 4, 2012, www.peoplespharmacy.com/2007/09/12/can-statins-cau.
24. Joe Graedon and Terry Graedon, “Does Lipitor Affect Memory and Nerves,” The People’s Pharmacy, April 18, 2005, accessed January 4, 2012, www.peoplespharmacy.com/2007/06/20/does-lipitor-af/.
25. B.A. Golomb et al., “Physician Response to Patient Reports of Adverse Drug Effects,” Drug Safety 30, no. 8 (2007): 669–75.
26. Ibid.
27. Susan Jeffrey, “ALLHAT Lipid-Lowering Trial Shows No Benefit from Pravastatin,” Heartwire, December 17, 2002, www.theheart.org/article/263333.do.
28. Heart Protection Study Collaborative Drug, “MRC/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial,” The Lancet 360, no. 9326 (2002): 7–22.
29. Uffe Ravnskov, “Statins as the New Aspirin,” British Medical Journal 324, no. 7340 (2002): 789.
30. Salynn Boyles, “More May Benefit from Cholesterol Drugs,” WebMD Health News, January 13, 2009, www.webmd.com/cholesterol-management/news/20090113/more-may-benefit-from-cholesterol-drugs.
31. Michel de Lorgeril et al., “Cholesterol Lowering, Cardiovascular Diseases, and the Rousuvastatin-JUPITER Controversy: A Critical Reappraisal,” Archives of Internal Medicine 170, no. 12 (2010): 1032–36.
32. Mark A. Hlatky, “Expanding the Orbit of Primary Prevention—Moving Beyond JUPITER,” New England Journal of Medicine 359 (2008): 2280–82.
33. Ibid.
34. H.S. Hecht and S.M. Harman, “Relation of Aggressiveness of Lipid-Lowering Treatment to Changes in Calcified Plaque Burden by Electron Beam Tomography,” American Journal of Cardiology 92, no. 3 (2003): 334–36.
35. W.A. Flegel, “Inhibition of Endotoxin-Induced Activation of Human Monocytes by Human Lipoprotein,” Infection and Immunity 57, no. 7 (1989): 2237–45; W.A. Flegel et al., “Prevention of Endotoxin-Induced Monokine Release by Human Low- and High-Density Lipoproteins and by Apolipoprotein A-I,” Infection and Immunity 61, no. 12 (1993): 5140–46; H. Northoff et al., “The Role of Lipoproteins in Inactivation of Endotoxin by Serum,” Beitr Infusionsther 30 (1992): 195–97.
36. Jacobs et al., “Report of the Conference on Low Blood Cholesterol.”
37. Iribarren et al., “Serum Total Cholesterol and Risk of Hospitalization”; Iribarren et al., “Cohort Study of Serum Total Cholesterol.”
38. Neaton and Wentworth, “Low Serum Cholesterol and Risk of Death from AIDS.”
39. Anne C. Looker et al., “Vitamin D Status: United States, 2001–2006,” Centers for Disease Control and Prevention, NCHS Data Brief No. 59, March 2011, www.cdc.gov/nchs/data/databriefs/db59.htm.
40. William Faloon, “Startling Findings About Vitamin D Levels in Life Extension Members,” Life Extension Magazine, January 2010, www.lef.org/magazine/mag2010/jan2010_Startling-Findings-About-Vitamin-D-Levels-in-Life-Extension-Members_01.htm.
41. Vitamin D Council, “Health Conditions,” Vitamin D Council, last modified September 27, 2011, www.vitamindcouncil.org/health-conditions.
42. Therapeutics Initiative, “About Us,” Therapeutics Initiative, http://ti.ubc.ca/about.
43. J.R. Downs et al., “Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels: Results of AFCAPS/TexCAPS,” Journal of the American Medical Association 279 (1998): 1615–22; J. Shepherd et al., “Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia,” New England Journal of Medicine 333 (1995): 1301–7.
44. Therapeutics Initiative, “Do Statins Have a Role in Primary Prevention?” Therapeutics Letter #48, April–June 2003, www.ti.ubc.ca/newsletter/do-statins-have-role-primary-prevention.
45. J. Abramson and J.M. Wright, “Are Lipid-Lowering Guidelines Evidence-Based?” The Lancet 369, no. 9557 (2007): 168–69.
46. M. Pignone et al., “Primary Prevention of CHD with Pharmacological Lipid-Lowering Therapy: A Meta-Analysis of Randomised Trials,” British Medical Journal 321, no. 7267 (2000): 983–86.
1. Eric G. Campbell, “Doctors and Drug Companies—Scrutinizing Influential Relationships,” New England Journal of Medicine 357 (2007): 1796–97; M.M. Chren, “Interactions Between Physicians and Drug Company Representatives,” American Journal of Medicine 107, no. 2 (1999): 182–83.
2. Heart Failure Society of America, “NYHA Classification—The Stages of Heart Failure,” Heart Failure Society of America, last modified December 5, 2011, www.abouthf.org/questions_stages.htm.
3. Per H. Langsjoen , S. Vadhanavikit, and K. Folkers, “Response of Patients in Classes III and IV of Cardiomyopathy to Therapy in a Blind and Crossover Trial with Coenzyme Q10,” Proceedings of the National Academy of Sciences of the United States of America 82, no. 12 (1985): 4240–44.
4. Per H. Langsjoen et al., “A Six-Year Clinical Study of Therapy of Cardiomyopathy with Coenzyme Q10,” International Journal of Tissue Reactions 12, no. 3 (1990): 169–71.
5. F.L. Rosenfeldt et al., “Coenzyme Q10 in the Treatment of Hypertension: A Meta-Analysis of the Clinical Trials,” Journal of Human Hypertension 21, no. 4 (2007): 297–306.
6. Sheldon Hendler, PDR for Nutritional Supplements, 2nd ed. (Montvale, NJ: PDR Network, 2008), 152.
7. P. Davini et al., “Controlled Study on L-Carnitine Therapeutic Efficacy in Post-Infarction,” Drugs Under Experimental and Clinical Research 18, no. 8 (1992): 355–65.
8. I. Rizos, “Three-Year Survival of Patients with Heart Failure Caused by Dilated Cardiomyopathy and L-Carnitine Administration,” American Heart Journal 139, no. 2 (2000): S120–23.
9. L. Cacciatore et al., “The Therapeutic Effect of L-Carnitine in Patients with Exercise-Induced Stable Angina: A Controlled Study,” Drugs Under Experimental and Clinical Research 17, no. 4 (1991): 225–35; G. Louis Bartels et al., “Effects of L-Propionylcarnitine on Ischemia-Induced Myocardial Dysfunction in Men with Angina Pectoris,” American Journal of Cardiology 74, no. 2 (1994): 125–30.
10. L.A. Calò et al., “Antioxidant Effect of L-Carnitine and Its Short Chain Esters: Relevance for the Protection from Oxidative Stress Related Cardiovascular Damage,” International Journal of Cardiology 107, no. 1 (2006): 54–60.
11. Mark J. Bolland et al., “Effects of Calcium Supplements on Risk of Myocardial Infarction and Cardiovascular Events: Meta-Analysis,” British Medical Journal 341, no. c3691 (2010).
12. P. Raggi et al., “Progression of Coronary Artery Calcium and Risk of First Myocardial Infarction in Patients Receiving Cholesterol-Lowering Therapy,” Arteriosclerosis, Thrombosis, and Vascular Biology 24, no. 7 (2004): 1272–77.
13. Ibid.
14. Udo Hoffmann et al., “Use of New Imaging Techniques to Screen for Coronary Artery Disease,” Circulation 108 (2003): e50–e53.
15. M.C. Houston and K.J. Harper, “Potassium, Magnesium, and Calcium: Their Role in Both the Cause and Treatment of Hypertension,” Journal of Clinical Hypertension 10, no. 7 (2008): 3–11; L. Widman et al., “The Dose-Dependent Reduction in Blood Pressure Through Administration of Magnesium: A Double-Blind Placebo-Controlled Crossover Trial,” American Journal of Hypertension 6, no. 1 (1993), 41–45.
16. P. Laurant and R.M. Touyz, “Physiological and Pathophysiological Role of Magnesium in the Cardiovascular System: Implications in Hypertension,” Journal of Hypertension 18, no. 9 (2000): 1177–91.
17. Robbert Meerwaldt et al., “The Clinical Relevance of Assessing Advanced Glycation Endproducts Accumulation in Diabetes,” Cardiovascular Diabetology 7, no. 29 (2008): 1–8; Andries J. Smit, “Advanced Glycation Endproducts in Chronic Heart Failure,” Annals of the New York Academy of Sciences 1126 (2008): 225–30; Jasper W.L. Hartog et al., “Advanced Glycation End-Products (AGEs) and Heart Failure: Pathophysiology and Clinical Implications,” European Journal of Heart Failure 9, no. 12 (2007): 1146–55.
18. A. Sjögren et al., “Oral Administration of Magnesium Hydroxide to Subjects with Insulin-Dependent Diabetes Mellitus: Effects on Magnesium and Potassium Levels and on Insulin Requirements,” Magnesium 7, no. 3 (1988): 117–22; Lima M. de Lordes et al., “The Effect of Magnesium Supplementation in Increasing Doses on the Control of Type 2 Diabetes,” Diabetes Care 21, no. 5 (1998): 682–86; G. Paolisso et al., “Dietary Magnesium Supplements Improve B-Cell Response to Glucose and Arginine in Elderly Non-Insulin Dependent Diabetic Subjects,” Acta Endocrinologica 121, no. 1 (1989): 16–20.
19. F. Guerrero-Romero and M. Rodríguez-Morán, “Low Serum Magnesium Levels and Metabolic Syndrome,” Acta Diabetologica 39, no. 4 (2002): 209–13.
20. National Institutes of Health, “Magnesium, What Is It?” Office of Dietary Supplements, National Institutes of Health, http://ods.od.nih.gov/factsheets/magnesium-HealthProfessional.
21. Sheldon Hendler, PDR for Nutritional Supplements, 2nd ed. (Montvale, NJ: PDR Network, 2008), 152.
22. E.S. Ford and A.H. Mokdad, “Dietary Magnesium Intake in a National Sample of U.S. Adults,” Journal of Nutrition 133, no. 9 (2003): 2879–82.
23. R. Altschul et al., “Influence of Nicotinic Acid on Serum Cholesterol in Man,” Archives of Biochemistry and Biophysics 54, no. 2 (1955): 558–59.
24. R.H. Knopp et al., “Contrasting Effects of Unmodified and Time-Release Forms of Niacin on Lipoproteins in Hyperlipidemic Subjects: Clues to Mechanism of Action of Niacin,” Metabolism 34, no. 7 (1985): 642–50; J.M. McKenney et al., “A Comparison of the Efficacy and Toxic Effects of Sustained vs. Immediate-Release Niacin in Hypercholesterolemic Patients,” Journal of the American Medical Association 271, no. 9 (1994): 672–77.
25. Pia R. Kamstrup, “Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction,” Journal of the American Medical Association 301, no. 22 (2009): 2331–39; M. Sandkamp et al., “Lipoprotein(a) Is an Independent Risk Factor for Myocardial Infarction at a Young Age,” Clinical Chemistry 36, no. 1 (1990): 20–23; A. Gurakar et al., “Levels of Lipoprotein Lp(a) Decline with Neomycin and Niacin Treatment,” Atherosclerosis 57, nos. 2–3 (1985): 293–301; L.A. Carlson et al., “Pronounced Lowering of Serum Levels of Lipoprotein Lp(a) in Hyperlipidaemic Subjects Treated with Nicotinic Acid,” Journal of Internal Medicine 226, no. 4 (1989): 271–76.
26. James Shepard et al., “Effects of Nicotinic Acid Therapy on Plasma High Density Lipoprotein Subfraction Distribution and Composition and on Apolipoprotein A Metabolism,” Journal of Clinical Investigation 63, no. 5 (1979): 858–67; G. Wahlberg et al., “Effects of Nicotinic Acid on Serum Cholesterol Concentrations of High Density Lipoprotein Subfractions HDL2 and HDL3 in Hyperlipoproteinaemia,” Journal of Internal Medicine 228, no. 2 (1990): 151–57.
27. Shepard et al., “Effects of Nicotinic Acid Therapy”; Wahlberg et al., “Effects of Nicotinic Acid on Serum Cholesterol.”
28. Alan Gaby, Nutritional Medicine (Concord, NH: Fritz Perlberg Publishing, 2011).
29. A. Hoffer, “On Niacin Hepatitis,” Journal of Orthomolecular Medicine 12 (1983): 90.
30. McKenney et al., “A Comparison of the Efficacy and Toxic Effects of Sustained Vs. Immediate-Release Niacin”; J.A. Etchason et al., “Niacin-Induced Hepatitis: A Potential Side Effect with Low-Dose Time-Release Niacin,” Mayo Clinic Proceedings 66, no. 1 (1991): 23–28.
31. Gaby, Nutritional Medicine.
32. E. Serbinova et al., “Free Radical Recycling and Intramembrane Mobility in the Antioxidant Properties of Alpha-Tocopherol and Alpha-Tocotrienol,” Free Radical Biology & Medicine 10, no. 5 (1991): 263–75.
33. R.A. Parker et al., “Tocotrienols Regulate Cholesterol Production in Mammalian Cells by Post-Transcriptional Suppression of 3-Hydroxy-3-Methylglutaryl-Coenzyme A reductase,” Journal of Biological Chemistry 268 (1993): 11230–38; B.C. Pearce et al., “Hypocholesterolemic Activity of Synthetic and Natural Tocotrienols,” Journal of Medicinal Chemistry 35, no. 20 (1992): 3595–606; B.C. Pearce et al., “Inhibitors of Cholesterol Biosynthesis. 2. Hypocholesterolemic and Antioxidant Activities of Benzopyran and Tetrahydronaphthalene Analogues of the tocotrienols,” Journal of Medicinal Chemistry 37, no. 4 (1994): 526–41.
34. S.G. Yu et al., “Dose-Response Impact of Various Tocotrienols on Serum Lipid Parameters in Five-Week-Old Female Chickens,” Lipids 41, no. 5 (2006): 453–61; M. Minhajuddin et al., “Hypolipidemic and Antioxidant Properties of Tocotrienol-Rich Fraction Isolated from Rice Bran Oil in Experimentally Induced Hyperlipidemic Rats,” Food and Chemical Toxicology 43, no. 5 (2005): 747–53; J. Iqbal et al., “Suppression of 7,12-Dimethyl-Benz[alpha]anthracene-Induced Carcinogenesis and Hypercholesterolaemia in Rats by Tocotrienol-Rich Fraction Isolated from Rice Bran Oil,” European Journal of Cancer Prevention 12, no. 6 (2003): 447–53; A.A. Qureshi et al., “Novel Tocotrienols of Rice Bran Suppress Cholesterogenesis in Hereditary Hypercholesterolemic Swine,” Journal of Nutrition 131, no. 2 (2001): 223–30; M.K. Teoh et al., “Protection by Tocotrienols against Hypercholesterolaemia and Atheroma,” Medical Journal of Malaysia 49, no. 3 (1994): 255–62; A.A. Qureshi et al., “Dietary Tocotrienols Reduce Concentrations of Plasma Cholesterol, Apolipoprotein B, Thromboxane B2, and Platelet Factor 4 in Pigs with Inherited Hyperlipidemias,” American Journal of Clinical Nutrition 53, no. 4 (1991): 1042S–46S; D. O’Byrne et al., “Studies of LDL Oxidation Following Alpha-, Gamma-, or Delta-Tocotrienyl Acetate Supplementation of Hypercholesterolemic Humans,” Free Radical Biology & Medicine 29, no. 9 (2000): 834–45; A.A. Qureshi et al., “Lowering of Serum Cholesterol in Hypercholesterolemic Humans by Tocotrienols (Palm Vitee),” American Journal of Clinical Nutrition 53, no. 4 supplement (1991): 1021–26; Qureshi et al., “Response of Hypercholesterolemic Subjects to Administration of Tocotrienols,” Lipids 30, no. 12 (1995): 1171–77; A.C. Tomeo et al., “Antioxidant Effects of Tocotrienols in Patients with Hyperlipidemia and Carotid Stenosis,” Lipids 30, no. 12 (1995): 1179–83.
35. Andrew Stoll, The Omega-3 Connection (New York: Free Press, 2001).
36. J. Dyerberg et al., “Plasma Cholesterol Concentration in Caucasian Danes and Greenland West Coast Eskimos,” Danish Medical Bulletin 24, no. 2 (1977): 52–55; H.O. Bang, et al., “The Composition of Food Consumed by Greenland Eskimos,” Acta Medica Scandinavica 200, nos. 1–2 (1976): 69–73; H.O. Bang and J. Dyerberg, “Plasma Lipids and Lipoproteins in Greenlandic West Coast Eskimos,” Acta Medica Scandinavica 192, nos. 1–2 (1972): 85–94; H.O. Bang et al., “Plasma Lipid and Lipoprotein Pattern in Greenlandic West Coast Eskimos,” The Lancet 1, no. 7710 (1971): 1143–45; J.Dyerberg et al., “Fatty Acid Composition of the Plasma Lipids in Greenland Eskimos,” American Journal of Clinical Nutrition 28, no. 9 (1975): 958–66.
37. D. Mozzafarian and J.H. Wu, “Omega-3 Fatty Acids and Cardiovascular Disease: Effects on Risk Factors, Molecular Pathways, and Clinical Events,” Journal of the American College of Cardiology 58, no. 20 (2011): 2047–67.
38. GISSI-Prevenzione Investigators, “Dietary Supplementation with N-3 Polyunsaturated Fatty Acids and Vitamin E after Myocardial Infarction: Results of the GISSI-Prevenzione Trial,” The Lancet 354, no. 9177 (1999): 447–55.
39. Martin R. Cowie, “The Clinical Benefit of Omega-3 PUFA Ethyl Esters Supplementation in Patients with Heart Failure,” European Journal of Cardiovascular Medicine 1, no. 2 (2010): 14–18.
40. National Institute for Health and Clinical Excellence, “Clinical Guidelines, CG48,” National Institute for Health and Clinical Excellence, last modified September 23, 2011, www.nice.org.uk/CG48.
41. Cowie, “The Clinical Benefit of Omega-3 PUFA Ethyl Esters.”
42. D. Lanzmann-Petithory, “Alpha-Linolenic Acid and Cardiovascular Diseases,” Journal of Nutrition, Health & Aging 5, no. 3 (2001): 179–83.
43. M. Yokoyama, “Effects of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: The Japan EPA Lipid Intervention Study (JELIS)” presentation, American Heart Association Scientific Sessions, Dallas, Texas, November 13–16, 2005; Medscape, “JELIS—Japan Eicosapentaenoic Acid (EPA) Lipid Intervention Study,” Medscape Education, www.medscape.org/viewarticle/518574.
44. G. Bon et al., “Effects of Pantethine on In Vitro Peroxidation of Low-Density Lipoproteins,” Atherosclerosis 57, no. 1 (1985): 99–106.
45. A.C. Junior et al., “Antigenotoxic and Antimutagenic Potential of an Annatto Pigment (Norbixin) Against Oxidative Stress,” Genetics and Molecular Research 4, no. 1 (2005): 94–99; G. Kelly, “Pantethine: A Review of its Biochemistry and Therapeutic Applications,” Alternative Medicine Review 2, no. 5 (1997): 365–77; F. Coronel et al., “Treatment of Hyperlipemia in Diabetic Patients on Dialysis with a Physiological Substance,” American Journal of Nephrology 11, no. 1 (1991): 32–36; P. Binaghi et al., “Evaluation of the Hypocholesterolemic Activity of Pantethine in Perimenopausal Women,” Minerva Medica 81 (1990): 475–79; Z. Lu, “A Double-Blind Clinical Trial: The Effects of Pantethine on Serum Lipids in Patients with Hyperlipidemia,” Chinese Journal of Cardiovascular Diseases 17, no. 4 (1989): 221–23; M. Eto et al., “Lowering Effect of Pantethine on Plasma Beta-Thromboglobulin and Lipids in Diabetes Mellitus,” Artery 15, no. 1 (1987): 1–12; D. Prisco et al., “Effect of Oral Treatment with Pantethine on Platelet and Plasma Phospholipids in Type II Hyperlipoproteinemia,” Angiology 38, no. 3 (1987): 241–47; F. Bellani et al., “Treatment of Hyperlipidemias Complicated by Cardiovascular Disease in the Elderly: Results of an Open Short-Term Study with Pantethine,” Current Therapeutic Research 40, no. 5 (1986): 912–16; S. Bertolini et al., “Lipoprotein Changes Induced by Pantethine in Hyperlipoproteinemic Patients: Adults and Children,” International Journal of Clinical Pharmacology and Therapeutics 24, no. 11 (1986): 630–37; C. Donati et al., “Pantethine Improves the Lipid Abnormalities of Chronic Hemodialysis Patients: Results of a Multicenter Clinical Trial,” Clinical Nephrology 25, no. 2 (1986): 70–74; L. Arsenio et al., “Effectiveness of Long-Term Treatment with Pantethine in Patients with Dyslipidemia,” Clinical Therapeutics 8, no. 5 (1986): 537–45; S. Giannini et al., “Efeitos da Pantetina Sobrelipides Sangineos,” Arquivos Brasileiros de Cardiologia 46, no. 4 (1986): 283–89; F. Bergesio et al., “Impiego della Pantetina nella Dislipidemia dell’Uremico Cronico in Trattamento Dialitico,” Journal of Clinical Medicine and Research 66, nos. 11–12 (1985): 433–40; G.F. Gensini et al., “Changes in Fatty Acid Composition of the Single Platelet Phospholipids Induced by Pantethine Treatment,” International Journal of Clinical Pharmacology Research 5, no. 5 (1985): 309–18; L. Cattin et al., “Treatment of Hypercholesterolemia with Pantethine and Fenofibrate: An Open Randomized Study on 43 Subjects,” Current Therapeutic Research 38 (1985): 386–95; A. Postiglione et al., “Pantethine Versus Fenofibrate in the Treatment of Type II Hyperlipoproteinemia,” Monographs on Atherosclerosis 13 (1985): 145–48; G. Seghieri et al., “Effetto della Terapia con Pantetina in Uremici Cronici Emodializzati con Iperlipoproteinemia di Tipo IV,” Journal of Clinical Medicine and Research 66, nos. 5–6 (1985): 187–92; L. Arsenio et al., “Iperlipidemia Diabete ed Aterosclerosi: Efficacia del Trattamento con Pantetina,” Acta Biomed Ateneo Parmense 55, no.1 (1984): 25–42; O. Bosello et al., “Changes in the Very Low Density Lipoprotein Distribution of Apolipoproteins C-III2, CIII1, C-III0, C-II, and Apolipoprotein E after Pantethine Administration,” Acta Therapeutica 10 (1984): 421–30; P. Da Col et al., “Pantethine in the Treatment of Hypercholesterolemia: A Randomized Double-Blind Trial Versus Tiadenol,” Current Therapeutic Research 36 (1984): 314–21; A. Gaddi et al., “Controlled Evaluation of Pantethine, a Natural Hypolipidemic Compound, in Patients with Different Forms of Hyperlipoproteinemia,” Atherosclerosis 50, no. 1 (1984): 73–83; R. Miccoli et al., “Effects of Pantethine on Lipids and Apolipoproteins in Hypercholesterolemic Diabetic and Non-Diabetic Patients,” Current Therapeutic Research 36 (1984): 545–49; M. Maioli et al., “Effect of Pantethine on the Subfractions of HDL in Dyslipidemic Patients,” Current Therapeutic Research 35 (1984): 307–11; G. Ranieri et al., “Effect of Pantethine on Lipids and Lipoproteins in Man,” Acta Therapeutica 10 (1984): 219–27; A. Murai et al., “The Effects of Pantethine on Lipid and Lipoprotein Abnormalities in Survivors of Cerebral Infarction,” Artery 12, no. 4 (1983): 234–43; P. Avogaro et al., “Effect of Pantethine on Lipids, Lipoproteins and Apolipoproteins in Man,” Current Therapeutic Research 33 (1983): 488–93; G. Maggi et al., “Pantethine: A Physiological Lipomodulating Agent in the Treatment of Hyperlipidemia,” Current Therapeutic Research 32 (1982): 380–86; K. Hiramatsu et al., “Influence of Pantethine on Platelet Volume, Microviscosity, Lipid Composition and Functions in Diabetes Mellitus with Hyperlipidemia,” Tokai Journal of Experimental and Clinical Medicine 6, no. 1 (1981): 49–57.
46. Mark Houston et al., “Nonpharmocologic Treatment of Dyslipidemia,” Progress in Cardiovascular Disease 52, no. 2 (2009): 61–94.
47. R. Pfister et al., “Plasma Vitamin C Predicts Incident Heart Failure in Men and Women in European Prospective Investigation into Cancer and Nutrition—Norfolk Prospective Study,” American Heart Journal 162, no. 2 (2011): 246–53.
48. W. Wongcharoen and A. Phrommintikul, “The Protective Role of Curcumin in Cardiovascular Diseases,” International Journal of Cardiology 133, no. 2 (2009): 145–51.
49. Mark Houston, What Your Doctor May Not Tell You About Heart Disease (New York: Grand Central Life & Style, 2012).
50. G. Ramaswami, “Curcumin Blocks Homocysteine-Induced Endothelial Dysfunction in Porcine Coronary Arteries,” Journal of Vascular Surgery 40, no. 6 (2004): 1216–22.
51. H. Sumi et al., “Enhancement of the Fibrinolytic Activity in Plasa by Oral Administration of Nattokinase,” Acta Haematologica 84, no. 3 (1990): 139–43.
52. Houston, What Your Doctor May Not Tell You.
53. M.A. Carluccio et al., “Olive Oil and Red Wine Antioxidant Polyphenols Inhibit Endothelial Activation: Antiatherogenic Properties of Mediterranean Diet Phytochemicals,” Atherosclerosis, Thrombosis, and Vascular Biology 23, no. 4 (2003): 622–29.
54. European Society of Cardiology, “Study Shows Chocolate Reduces Blood Pressure and Risk of Heart Disease,” European Society of Cardiology, March 31, 2010, www.escardio.org/about/press/press-releases/pr-10/Pages/chocolate-reduces-blood-pressure.aspx.
55. Mark Houston et al., “Nonpharmologic Treatment for Dyslipideia,” Progress in Cardiovascular Disease 52, no. 2 (2009), 61–94.
1. Rick Relyea, “Predator Cues and Pesticides: A Double Dose of Danger,” Ecological Applications 13, no. 6 (2003): 1515–21.
2. Julia C. Buck, “The Effects of Multiple Stressors on Wetland Communities: Pesticides, Pathogens, and Competing Amphibians,” Freshwater Biology 57, no. 1 (2012): 61–73; Qin Guangqiu et al., “Effects of Predator Cues on Pesticide Toxicity: Toward an Understanding of the Mechanism of the Interaction,” Environmental Toxicology and Chemistry 30, no. 8 (2011): 1926–34; Maya L. Groner and Rick Relyea, “A Tale of Two Pesticides: How Common Insecticides Affect Aquatic Communities,” Freshwater Biology 56, no. 11 (2011): 2391–404; Andrew Sih et al., “Two Stressors Are Far Deadlier than One,” Trends in Ecology and Evolution 19, no. 6 (2004): 274–76.
3. Robert Sapolsky, “Stress and Your Body,” Lecture 3, The Great Courses: Teaching Company.
4. World Heart Federation, “Hypertension,” World Heart Federation, www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/hypertension.
5. Robert Sapolsky, “Stress and Your Body” (Lecture 3, The Great Courses: Teaching Company).
6. Medical News Today, “Mental Stress Raises Cholesterol Levels in Healthy Adults,” Medical News Today, November 23, 2005, www.medicalnewstoday.com/releases/34047.php.
7. Miranda Hitti, “Cut Stress, Help Your Cholesterol,” WebMD Health News, November 22, 2005, www.webmd.com/cholesterol-management/news/20051122/cut-stress-help-your-cholesterol.
8. A.H. Glassman et al., “Psychiatric Characteristics Associated with Long-Term Mortality Among 361 Patients Having an Acute Coronary Syndrome and Major Depression: Seven-Year Follow-Up of SADHART Participants,” Archives of General Psychiatry 66, no. 9 (2009): 1022–29.
9. A.H. Glassman, “Depression and Cardiovascular Comorbidity,” Dialogues in Clinical Neuroscience 9, no. 1 (2007): 9–17.
10. Stephen Sinatra, Heart Break and Heart Disease (Chicago: Keats Publishing, 1996).
11. Rana Foroohar, “The Optimist: Why Warren Buffet Is Bullish on America,” Time, January 23, 2012.
12. Ibid.
1. Johns Hopkins Medicine, “The New Blood Lipid Tests—Sizing Up LDL Cholesterol,” Johns Hopkins Health Alerts, last modified on June 13, 2008, www.johnshopkinshealthalerts.com/reports/heart_health/1886-1.html.
2. James J. Stec et al., “Association of Fibrinogen with Cardiovascular Risk Factors and Cardiovascular Disease in the Framingham Offspring Population,” Circulation 102, no. 14 (2000): 1634–38.
3. Ibid; Lisa Nainggolan, “Fibrinogen Tests Should Be Used for Additional Information when Assessing Cardiovascular Disease,” Heartwire, October 3, 2000, www.theheart.org/article/180167.do.
4. Stec et al., “Association of Fibrinogen with Cardiovascular Risk Factors.”
5. J.T. Salonen et al., “High Stored Iron Levels Are Associated with Excess Risk of Myocardial Infarction in Eastern Finnish Men,” Circulation 86, no. 3 (1992): 803–11; Lawrence K. Altman, “High Level of Iron Tied to Heart Risk,” New York Times, September 8, 1992.
6. Salonen et al., “High Stored Iron Levels.”
7. Vitamin C Foundation, “Statins Can Damage Your Health,” Vitamin C Foundation, www.vitamincfoundation.org/statinalert.
8. H. Refsum et al., “The Hordaland Homocysteine Study: A Community-Based Study of Homocysteine, Its Determinants, and Associations with Disease,” Journal of Nutrition 136, no. 6 (2006): 1731S–40S; Homocystein Studies Collaboration, “Homocysteine and Risk of Ischemic Heart Disease and Stroke: A Meta-Analysis,” Journal of the American Medical Association 288, no. 16 (2002): 2015–22; D.S. Wald et al., “Homocysteine and Cardiovascular Disease: Evidence on Casualty from a Meta-Analysis,” British Medical Journal 325, no. 7374 (2002): 1202.
9. D.S. Wald et al., “The Dose-Response Relation Between Serum Homocysteine and Cardiovascular Disease: Implications for Treatment and Screening,” European Journal of Cardiovascular Prevention and Rehabilitation 11, no. 3 (2004): 250–53.
10. Moti Haim et al., “Serum Homocysteine and Long-Term Risk of Myocardial Infarction and Sudden Death in Patients with Coronary Heart Disease,” Cardiology 107, no. 1 (2007): 52–56.
11. Mark Houston, What Your Doctor May Not Tell You About Heart Disease (New York: Grand Central Life & Style, 2012).
12. S. Seely, “Is Calcium Excess in Western Diet a Major Cause of Arterial Disease?” International Journal of Cardiology 33, no. 2 (1991): 191–98.
13. Udo Hoffmann, Thomas J. Brady, and James Muller, “Use of New Imaging Techniques to Screen for Coronary Artery Disease,” Circulation 108 (2003): e50–e53
14. Ibid.
15. Kimber L. Stanhope et al., “Consumption of Fructose and High-Fructose Corn Syrup Increase Postprandial Triglycerides, LDL-Cholesterol, and Apolipoprotein-B in Young Men and Women,” Journal of Clinical Endocrinology & Metabolism 96, no. 10 (2011): E1596–605; Science Daily, “Fructose Consumption Increases Risk Factors for Heart Disease: Study Suggests US Dietary Guideline for Upper Limit of Sugar Consumption Is Too High,” Science Daily, July 28, 2011, www.sciencedaily.com/releases/2011/07/110728082558.htm; Kimber L. Stanhope and Peter J. Havel, “Endocrine and Metabolic Effects of Consuming Beverages Sweetened with Fructose, Glucose, Sucrose, or High-Fructose Corn Syrup,” American Journal of Clinical Nutrition 88, no. 6 (2008): 1733S–37S.
16. S. Sieri et al., “Dietary Glycemic Load and Index and Risk of Coronary Heart Disease in a large Italian Cohort: The EPICOR Study,” Archives of Internal Medicine 12, no. 170 (2010): 640–47.
17. Tel Aviv University, “How High Carbohydrate Foods Can Raise Risk For Heart Problems,” ScienceDaily, June 25, 2009, retrieved February 8, 2012, from www.sciencedaily.com/releases/2009/06/090625133215.htm
18. Science Daily, “How High Carbohydrate Foods Can Raise Risk for Heart Problems,” Science Daily, June 25, 2009, retrieved February 8, 2012, www.sciencedaily.com/releases/2009/06/090625133215.htm.
19. Simin Liu et al., “Relation Between a Diet with a High Glycemic Load and Plasma Concentrations of High-Sensitivity C-Reactive Protein in Middle-Aged Women,” American Journal of Clinical Nutrition 75, no. 3 (2002): 492–98.
20. Ibid.
21. Charlene Laino, “Trans Fats Up Heart Disease Risk,” WebMD Health News, November 15, 2006, www.webmd.com/heart/news/20061115/heart-disease-risk-upped-by-trans-fats.
22. Frank B. Hu et al., “Dietary Fat Intake and the Risk of Coronary Heart Disease in Women,” New England Journal of Medicine 337, no. 21 (1997): 1491–99.
23. Institute of Medicine of the National Academies, Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Washington, D.C.: The National Academies Press, 2005), 504.
24. Harvard School of Public Health, “Eating Processed Meats, but Not Unprocessed Red Meats, May Raise Risk of Heart Disease and Diabetes,” news release, May 17, 2010, www.hsph.harvard.edu/news/press-releases/2010-releases/processed-meats-unprocessed-heart-disease-diabetes.html.
25. Ibid.
26. Jonny Bowden, The 150 Healthiest Foods on Earth (Beverly, MA: Fair Winds Press, 2007).
27. L. Zhang et al., “Pterostilbene Protects Vascular Endothelial Cells Against Oxidized Low-Density Lipoprotein-Induced Apoptosis In Vitro and In Vivo,” Apoptosis 17, no. 1 (2012): 25–36.
28. H.C. Ou et al., “Ellagic Acid Protects Endothelial Cells from Oxidized Low-Density Lipoprotein-Induced Apoptosis by Modulating the PI3K/Akt/eNOS Pathway,” Toxicology and Applied Pharmacology 248, no. 2 (2010): 134–43.
29. H.C. Hung et al., “Fruit and Vegetable Intake and Risk of Major Chronic Disease,” Journal of the National Cancer Institute 96, no. 21 (2004): 1577–84.
30. Ibid.
31. F.J. He et al., “Increased Consumption of Fruit and Vegetables Is Related to a Reduced Risk of Coronary Heart Disease: Meta-Analysis of Cohort Studies,” Journal of Human Hypertension 21, no. 9 (2007): 717–28.
32. F.J. He et al., “Fruit and Vegetable Consumption and Stroke: Meta-Analysis of Cohort Studies,” The Lancet 367, no. 9507 (2006): 320–26.
33. H.C. Hung et al., “Fruit and Vegetable Intake and Risk of Major Chronic Disease,” Journal of the National Cancer Institute 96, no. 21 (2004): 1577–84.
34. Bowden, The 150 Healthiest Foods on Earth.
35. Dariush Mozaffarian et al., “Changes in Diet and Lifestyle and Long-Term Weight Gain in Men and Women,” New England Journal of Medicine 364, no. 25 (2011): 2392–404.
36. Marian Burros, “Eating Well; Pass the Nuts, Pass Up the Guilt,” New York Times, January 15, 2003.
37. Oscar H. Franco et al., “The Polymeal: A More Natural, Safer, and Probably Tastier (than the Polypill) Strategy to Reduce Cardiovascular Disease by More Than 75%,” British Medical Journal 329, no. 7480 (2004): 1447.
38. D.M. Winham et al., “Pinto Bean Consumption Reduces Biomarkers for Heart Disease Risk,” Journal of the American College of Nutrition 26, no. 3 (2007): 243–49.
39. E.K. Kabagambe et al., “Decreased Consumption of Dried Mature Beans Is Positively Associated with Urbanization and Nonfatal Acute Myocardial Infarction,” Journal of Nutrition 135, no. 7 (2005): 1770–75.
40. Bazzano et al., “Legume Consumption and Risk of Coronary Heart Disease in U.S. Men and Women,” Archives of Internal Medicine 161, no. 21 (2001): 2573–78.
41. Adriana Buitrago-Lopez et al., “Chocolate Consumption and Cardiometabolic Disorders: Systematic Review and Meta-Analysis,” British Medical Journal 343 (2011): d4488.
42. S. Desch et al., “Effect of Cocoa Products on Blood Pressure: Systemic Review and Meta-Analysis,” Abstract, American Journal of Hypertension 23, no. 1 (2010): 97–103.
43. Brian Buijsse et al., “Cocoa Intake, Blood Pressure, and Cardiovascular Mortality,” Archives of Internal Medicine 166, no. 4 (2006): 411–17.
44. Michael Aviram et al., “Pomegranate Juice Consumption Reduces Oxidative Stress, Atherogenic Modifications to LDL, and Platelet Aggregation: Studies in Humans and in Atherosclerotic Apolipoprotein E–Deficient Mice,” American Journal of Clinical Nutrition 71, no. 5 (2000): 1062–76; Michael Aviram et al., “Pomegranate Juice Flavonoids Inhibit Low-Density Lipoprotein Oxidation and Cardiovascular Diseases: Studies in Atherosclerotic Mice and in Humans,” Drugs Under Experimental and Clinical Research 28, no. 2–3 (2002): 49–62.
45. Michael Aviram et al., “Pomegranate Juice Consumption for 3 Years by Patients with Carotid Artery Stenosis Reduces Common Carotid Intima-Media Thickness, Blood Pressure and LDL Oxidation,” Clinical Nutrition 23, no. 3 (2004): 423–33.
46. L.J. Ignarro et al., “Pomegranate Juice Protects Nitric Oxide Against Oxidative Destruction and Enhances the Biological Actions of Nitric Oxide,” Nitric Oxide 15, no. 2 (2006): 93–102.
47. D.K. Das et al., “Cardioprotection of Red Wine: Role of Polyphenolic Antioxidants,” Drugs Under Experimental and Clinical Research 25, nos. 2–3 (1999): 115–20.
48. V. Ivanov at al., “Red Wine Antioxidants Bind to Human Lipoproteins and Protect them from Metal Ion-Dependent and Independent Oxidation,” Journal of Agriculture and Food Chemistry 49, no. 9 (2001): 4442–49; M. Aviram and B. Fuhrman, “Wine Flavonoids Protect Against LDL Oxidation and Atherosclerosis,” Annals of the New York Academy of Sciences 957 (2002): 146–61.
49. A. Lugasi et al., “Cardio-Protective Effect of Red Wine as Reflected in the Literature,” Abstract, Orvosi Hetilap 138, no. 11 (1997): 673–78; T.S. Saleem and S.D. Basha, “Red Wine: A Drink to Your Heart,” Journal of Cardiovascular Disease Research 1, no. 4 (2010): 171–76.
50. Demosthenes B. Panagiotakos et al., “Mediterranean Diet and Inflammatory Response in Myocardial Infarction Survivors,” International Journal of Epidemiology 38, no. 3 (2009): 856–66.
51. J. Sano, “Effects of Green Tea Intake on the Development of Coronary Artery Disease,” Circulation Journal 68, no. 7 (2004): 665–70.
52. Stephen L. Duffy, “Short- and Long-Term Black Tea Consumption Reverses Endothelial Dysfunction in Patients with Coronary Artery Disease,” Circulation 104 (2001): 151–56.
53. Medscape, “Black Tea Shown to Improve Blood Vessel Health,” Medscape News, July 17, 2001, www.medscape.com/viewarticle/411324.
54. Antonia Trichopoulou et al., “Mediterranean Diet and Survival Among Patients with Coronary Heart Disease in Greece,” Archives of Internal Medicine 165, no. 8 (2005): 929–35.
55. Aldo Ferrera et al., “Olive Oil and Reduced Need for Antihypertensive Medications,” Archives of Internal Medicine 160, no. 6 (2000): 837–42.
56. Science Daily, “Olive Oil Contains Natural Anti-Inflammatory Agent,” Science Daily, September 6, 2005, www.sciencedaily.com/releases/2005/09/050906075427.htm.
57. American Botanical Council, “Garlic,” Herbalgram, http://cms.herbalgram.org/expandedE/Garlic.html.
58. Jonny Bowden, The Most Effective Natural Cures on Earth (Beverly, MA: Fair Winds Press, 2008).
59. J.W.Pennebaker, Opening Up: The Healing Power of Expressing Emotions (New York: Guilford Press, 1997); J. Frattaroli, “Experimental Disclosure and Its Moderators: A Meta-Analysis,” Psychological Bulletin 132, no. 6 (2006): 823–65.